semaglutide and parkinson's Glucagon-like peptide-1 class drugs show clear protective effects in Alzheimer's disease clinical trials: A revolution in the making? semaglutide alzheimer's Unlocking the Potential:

Researchers and leading pharma scientists now ask: could GLP-1s be our first true longevity drugs

Same destination, radically different comfort

The MHRA approved Wegovy specifically for cardiovascular risk reduction based on a large-scale clinical trial that showed significant benefits

[4] Pharmacokinetic interaction data remain sparse, yet in vitro assays show moderate inhibition of hepatic CYP3A4 and CYP2D6 at supraphysiologic concentrations, raising theoretical concerns for drugs with narrow therapeutic indices such as cyclosporine, certain anti-arrhythmics, or antidepressants

Mean pulse rate increased more in the orforglipron groups at 1 year than the semaglutide groups, but the percentage of adults who experienced treatment-emergent tachycardia or persistent tachycardia was similar with orforglipron and semaglutide

0% on placebo